In the last trading session, 1.44 million Avidity Biosciences Inc (NASDAQ:RNA) shares changed hands as the company’s beta touched 0.99. With the company’s per share price at $33.83 changed hands at $2.72 or 8.74% during last session, the market valuation stood at $4.07B. RNA’s last price was a discount, traded about -65.53% off its 52-week high of $56.00. The share price had its 52-week low at $21.56, which suggests the last value was 36.27% up since then. When we look at Avidity Biosciences Inc’s average trading volume, we note the 10-day average is 1.29 million shares, with the 3-month average coming to 1.36 million.
Analysts gave the Avidity Biosciences Inc (RNA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.07. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended RNA as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Avidity Biosciences Inc’s EPS for the current quarter is expected to be -0.88.
Avidity Biosciences Inc (NASDAQ:RNA) trade information
Instantly RNA was in green as seen at the end of in last trading. With action 12.62%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 16.33%, with the 5-day performance at 12.62% in the green. However, in the 30-day time frame, Avidity Biosciences Inc (NASDAQ:RNA) is 2.45% up. Looking at the short shares, we see there were 16.95 million shares sold at short interest cover period of 12.51 days.
The consensus price target for the stock as assigned by Wall Street analysts is 59, meaning bulls need an upside of 42.66% from its current market value. According to analyst projections, RNA’s forecast low is 59 with 59 as the target high. To hit the forecast high, the stock’s price needs a -74.4% plunge from its current level, while the stock would need to soar -74.4% for it to hit the projected low.
Avidity Biosciences Inc (RNA) estimates and forecasts
Year-over-year growth is forecast to reach -15.80% down from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 2.62M. 8 analysts are of the opinion that Avidity Biosciences Inc’s revenue for the current quarter will be 2.51M. The company’s revenue for the corresponding quarters a year ago was 3.54M and 2.04M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -26.10%. The estimates for the next quarter sales put growth at 22.77%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -34.37%. The 2025 estimates are for Avidity Biosciences Inc earnings to decrease by -32.24%, but the outlook for the next 5-year period is at 0.06% per year.
RNA Dividends
Avidity Biosciences Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Avidity Biosciences Inc (NASDAQ:RNA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.99% of Avidity Biosciences Inc shares while 107.32% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 112.96%. There are 107.32% institutions holding the Avidity Biosciences Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 18.5285% of the shares, roughly 16.16 million RNA shares worth $660.1 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 12.5173% or 10.92 million shares worth $445.94 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund . With 4.43 shares estimated at $149.8 million under it, the former controlled 3.68% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.91% of the shares, roughly 3.5 shares worth around $118.46 million.
